Eluminex Starts Trials of Novel Trispecific Fusion mAb for Macular Edema

Suzhou’s Eluminex Biosciences was approved to start US trials of its novel trispecific fusion antibody aimed at treating diabetic macular edema. EB-105 targets VEGF-A, VEGF-B, placental growth factor, angiopoetin-2, and interleukin-6 receptor. Eluminex believes that high levels of IL-6 may cause persistent refractory edema in DME patients who are currently being treated with existing drugs. The ability of EB-105 to inhibit several biological pathways simultaneously may offer better efficacy than present therapies, it added. Eluminex has raised over $100 million from investors including Lilly Asia Ventures, Quan Capital, Hillhouse Ventures, and Cenova Capital. More details....

Share this with colleagues: